More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes

Peer Review reports

Original Submission
18 Oct 2017	Submitted	Original manuscript
9 Nov 2017	Author responded	Author comments - Rory Michael Shallis
Resubmission - Version 2
9 Nov 2017	Submitted	Manuscript version 2
13 Nov 2017	Author responded	Author comments - Rory Michael Shallis
Resubmission - Version 3
13 Nov 2017	Submitted	Manuscript version 3
Publishing
4 Jan 2018	Editorially accepted
1 Feb 2018	Article published	10.1186/s12878-018-0095-2

Back to article page